SCM
UBX

Sio Capital Management’s Unity Biotechnology UBX Stock Holding History

Sio Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,064
Closed -$956K – 86
2019
Q2 		$956K Buy
+10,064
New +$856K 0.23% 64

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sio Capital Management's UBX Position: Q3 2019 in Review

Sio Capital Management sold out of Unity Biotechnology (UBX) in Q3 2019, closing a stake of 10,064 shares — an estimated $956K sold.

Sio Capital Management first reported a position in UBX in Q2 2019 and held it in 1 quarter. The position peaked at $956K in Q2 2019. 63 funds tracked by Wall St. Rank hold UBX as of Q3 2019.

  • Sio Capital Management reported no remaining Unity Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Sio Capital Management sold 10,064 Unity Biotechnology shares in Q3 2019, an estimated $956K.
  • Sio Capital Management first reported a position in Unity Biotechnology in Q2 2019 and held it in 1 quarter.
  • Sio Capital Management's Unity Biotechnology position peaked at $956K in Q2 2019.
  • 63 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2019.

Based on Sio Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.